DuPont, one of a leading market-driven science companies, expects full-year 2011 sales to be up about 20 per cent, with double digit increases in most segments, said a top official.

“DuPont expects nearly $12 billion of revenue from products introduced in the previous four years, roughly 30 percent of company sales in 2011.  That demonstrates the power of our innovation,” remarked Ellen Kullman, the chair and CEO of DuPont.

Affirming strong long-term growth outlook, Kullman said, "Innovation, differential management and productivity will remain key drivers for 2012 and beyond. The sales in developing markets are expected to jump 30 per cent this year, comprising about one-third of total company sales."

"Earnings are expected to be up between 18 to 20 per cent. These results reflect a comprehensive approach to target and grow in these markets, including opening new innovation centers in South Korea, Taiwan, Thailand and India in 2011," she added.

Kullman was speaking at DuPont’s 2011 Investor Day which was attended by company’s senior leaders and other top officials.

She detailed the dynamic growth strategy for continuing to deliver strong, sustainable results in 2012 and beyond, contributing to 7 and 12 percent compound annual growth rates for sales and earnings, respectively, in the coming years.

At the Investor Day, Kullman and senior leaders highlighted many DuPont success stories, including the blockbusters Optimum AcreMax family of seed products and Rynaxypyr insect control, and other significant achievements in nutrition, industrial biosciences, electronic materials and advanced protection materials.

"DuPont is differentially managing its portfolio to deliver solutions that meet the food, energy and protection challenges of a growing global population," she noted.

By conducting a critical analysis of each business, its market position, capabilities and ability to differentiate versus competition, we can drive the most compelling opportunities for long-term growth,” Kullman said.

"Approximately 75 per cent of our capital and R&D expenditures are allocated to growth segments," she stated.

Kullman pointed out that DuPont will deliver $300 million of both fixed cost and working capital productivity in 2012.

“Our long-term growth profile reflects the strength of our portfolio, innovations and ongoing benefits from disciplined productivity efforts,” Kullman said.

DuPont leaders outlined specific long-term growth targets and priorities for company’s key  segments including agriculture, nutrition and health.-TradeArabia News Service